www.onkologiecs.cz 203 / Onkologie. 2025;19(4):198-203 / ONKOLOGIE HLAVNÍ TÉMA REIRADIACE NÁDORŮ ORL OBLASTI. MÁ SMYSL? – ZKUŠENOSTI A VÝSLEDKY LÉČBY Z ÚRO 1. LF UK A FNB OD R. 2003 DO R. 2023 LITERATURA 1. Švajdová M, Kazda T, Dubinský P, et al. Radikální reiradiace rekurentních nádorů hlavy a krku s využitím zevní radioterapie. Klin Onkol. 2021;34(2):103-112. 2. Gordon K, Smyk D, Gulidov I, et al. An Overview of Head and Neck Tumor Reirradiation: What Has Been Achieved So Far? Cancers (Basel). 2023;15(17):4409. doi: 10.3390/cancers15174409. PMID: 37686685; PMCID: PMC10486419. 3. Mastronicola R, Le Roux P, Casse A, et al. Current Approaches to Salvage Surgery for Head and Neck Cancer: A Comprehensive Review. Cancers (Basel). 2023;15(9):2625. doi: 10.3390/cancers15092625. PMID: 37174091; PMCID: PMC10177213. 4. Chen AM, Harris JP, Nabar R, et al. Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer. Radiother Oncol. 2024;196:110278. doi: 10.1016/j.radonc.2024.110278. Epub 2024 Apr 16. PMID: 3863. 5. Guigay J, Aupérin A, Fayette J. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463-475. doi: 10.1016/S14702045(20)30755-5. Epub 2021 Mar 5. PMID: 33684370. 6. Merck Sharp & Dohme LLC. A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/ KEYNOTE-048). ClinicalTrials.gov, Last up-date: 2024-09-20. 7. Merck Sharp & Dohme LLC. Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475412/KEYNOTE-412). ClinicalTrials.gov, Last up-date: 2024-09-19. 8. Chen AM, Harris JP, Nabar R, et al. Re-irradiation with concurrent pembrolizumab for local-regionally recurrent squamous cell carcinoma of the head and neck. ScienceDirect, Elsevier, Oral Oncology Reports. March 2025;13. 9. Ward MC, Lee NY, Caudell JJ, et al. A competing risk nomogram to predict severe late toxicity after modern reirradiation for squamous carcinoma of the head and neck. Oral Oncol. 2019;90:80-86. doi: 10.1016/j.oraloncology.2019.01.022. Epub 2019 Feb 8. PMID: 30846182. 10. McDonald MW, Moore MG, Johnstone PA. Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int J Radiat Oncol Biol Phys. 2012;82(3):1083-1089. doi: 10.1016/j.ijrobp.2010.08.029. Epub 2011 May 5. PMID: 21549520. 11. Lee HI, Kim JH, Ahn SH, et al. Re-irradiation for recurrent or second primary head and neck cancer, Radiat Oncol J. 2021;39(4):279-287. doi: 10.3857/roj.2021.00640. Epub 2021 Dec 7. PMID: 34986549; PMCID: PMC8743457. 12. Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for reccurent head and neck cancer, Int J Radiat Oncol Biol Phys. 2007;68(3):731-740. doi: 10.1016/j.ijrobp.2006.12.055. Epub 2007 Mar 26. PMID: 17379449. 13. Eekers DBP, Roelofs E, Jelen U, et al. Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiother Oncol. 2016;121(3):387-394. doi: 10.1016/j.radonc.2016.08.020. Epub 2016 Sep 14. PMID: 2763. 14. Göttgens EL, Ostheimer C, Span PN, et al. HPV, hypoxia and radiation response in head and neck cancer, Br J Radiol. 2019;92(1093):20180047. doi: 10.1259/bjr.20180047. Epub 2018 Mar 14. PMID: 29493265; PMCID: PMC6435089. Graf 3. Medián přežití od ukončení re-RT na ÚRO FNB mezi lety 2003 a 2023 Graf 4. Medián přežití od data diagnózy relapsu na ÚRO FNB mezi lety 2003 a 2023 Complete Censored -1 0 1 2 3 4 5 6 7 8 9 101112131415 Čas (roky) -0,2 -0,1 0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1,0 % přežívajících pacientů Complete Censored -1 0 1 2 3 4 5 6 7 8 9 101112131415 Čas (roky) -0,2 -0,1 0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,7 0,8 0,9 1,0 % přežívajících pacientů pro mladé lékaře… první kongres zdarma pro absolventy 40% sleva pro lékaře do 35 let na: předplatné našich časopisů námi pořádané kongresy brigády pro studenty medicíny Nabídka Solenu
RkJQdWJsaXNoZXIy NDA4Mjc=